Insider Selling: Tempus AI, Inc. (NASDAQ:TEM) Director Sells 620 Shares of Stock

Tempus AI, Inc. (NASDAQ:TEM) Director David R. Epstein sold 620 shares of the stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $41.81, for a total transaction of $25,922.20. Following the sale, the director now directly owns 27,894 shares of the company’s stock, valued at approximately $1,166,248.14. This trade represents a 2.17 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Tempus AI Stock Down 2.4 %

NASDAQ TEM traded down $0.99 during trading on Friday, hitting $41.00. The stock had a trading volume of 5,041,241 shares, compared to its average volume of 1,427,998. Tempus AI, Inc. has a one year low of $22.89 and a one year high of $79.49. The firm’s 50 day moving average price is $52.88. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55.

Analysts Set New Price Targets

A number of analysts have issued reports on the stock. Wolfe Research assumed coverage on shares of Tempus AI in a report on Friday. They issued an “outperform” rating and a $60.00 price target on the stock. Loop Capital increased their target price on Tempus AI from $48.00 to $57.00 and gave the company a “buy” rating in a research report on Tuesday, October 15th. Bank of America boosted their price target on shares of Tempus AI from $52.00 to $54.00 and gave the stock a “neutral” rating in a research report on Friday. Piper Sandler reiterated a “neutral” rating and set a $70.00 price objective (up previously from $40.00) on shares of Tempus AI in a research report on Tuesday, November 12th. Finally, Stifel Nicolaus cut shares of Tempus AI from a “buy” rating to a “hold” rating and upped their target price for the company from $45.00 to $65.00 in a research report on Monday, November 11th. Three analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, Tempus AI presently has an average rating of “Moderate Buy” and an average price target of $56.00.

Institutional Investors Weigh In On Tempus AI

A number of institutional investors and hedge funds have recently modified their holdings of the business. EFG Asset Management North America Corp. purchased a new stake in Tempus AI in the second quarter worth $1,333,000. ARK Investment Management LLC bought a new position in shares of Tempus AI in the second quarter worth about $18,294,000. Northwestern University purchased a new position in Tempus AI in the 2nd quarter worth about $491,000. Alphabet Inc. purchased a new stake in Tempus AI in the 2nd quarter valued at about $54,289,000. Finally, Pier Capital LLC bought a new position in Tempus AI in the 2nd quarter worth about $2,301,000. 24.22% of the stock is owned by institutional investors.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.